Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Blood (2024) 144 (Supplement 1): 607.

https://doi.org/10.1182/blood-2024-200367

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Journal Articles

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 895.

https://doi.org/10.1182/blood-2023-187622

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Feasibility of Cellular Therapies in HIV Infected Patients: A Monocentric Retrospective Analysis

Luca Inchiappa, Gabriel Brisou, Benjamin Bouchacourt, Samia Harbi, Faezeh Legrand, Raynier Devillier, Hélène Laroche, Olivia Faucher, Sylvie Bregigeon, Christian Chabannon, Marie-Anne Hospital, Norbert Vey, Didier Blaise, Sabine Furst

Blood (2022) 140 (Supplement 1): 12959–12960.

https://doi.org/10.1182/blood-2022-167144

Published: 2022

Journal Articles

Prep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation

Claude Lemarié, Bechara Mfarrej, Sabine Furst, Didier Blaise, Sylvie Bayona, Benjamin Bouchacourt, Boris Calmels, Raynier Devillier, Catherine Faucher, Angela Granata, Samia Harbi, Faezeh Legrand, Thomas Pagliardini, Christophe Picard, Sandrine Sow, Sophie Simon, Cécile Teste, Fluzin Sylvain, Christian Chabannon

Blood (2022) 140 (Supplement 1): 12811–12812.

https://doi.org/10.1182/blood-2022-162290

Published: 2022

Journal Articles

Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic - a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT

Nina Worel, Per T Ljungman, Isabel Sánchez-Ortega, Jorinde D Hoogenboom, Nina S Knelange, Inge CM Verheggen, Dirk-Jan Eikema, Annalisa Ruggeri, Jurgen Kuball, Diana Averbuch, Rafael De La Camara, Christian Chabannon

Blood (2022) 140 (Supplement 1): 10439–10440.

https://doi.org/10.1182/blood-2022-165383

Published: 2022

Journal Articles

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Blood (2022) 140 (Supplement 1): 10413–10415.

https://doi.org/10.1182/blood-2022-169037

Published: 2022

Journal Articles

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Pauline Roché, Gabriel Brisou, Sabine Furst, Robin Noel, Catalina Montes De Oca, Aude Collignon, Luca Inchiappa, Jean Marc Schiano De Colella, Isabelle Brenot Rossi, Thibaut Reichert, Sophie Thévenet, Bechara Mfarrej, Boris Calmels, Didier Blaise, Christian Chabannon, Raynier Devillier

Blood (2022) 140 (Supplement 1): 7740–7741.

https://doi.org/10.1182/blood-2022-157915

Published: 2022

Journal Articles

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Moniek de Witte, Jorinde Hoogenboom, Jarl Mooyaart, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jurgen Kuball

Blood (2022) 140 (Supplement 1): 4741–4742.

https://doi.org/10.1182/blood-2022-157422

Published: 2022

Journal Articles

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2022) 140 (Supplement 1): 10389–10390.

https://doi.org/10.1182/blood-2022-158880

Published: 2022

Journal Articles

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Blood (2022) 140 (Supplement 1): 7712–7713.

https://doi.org/10.1182/blood-2022-158171

Published: 2022

Journal Articles

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2022) 140 (Supplement 1): 4664–4667.

https://doi.org/10.1182/blood-2022-168614

Published: 2022

Journal Articles

Higher Grade Cytokine Release Syndrome Is a Predictive Factor for Gvhd in Haploidentical Stem Cell Transplantation with Peripheral Blood Cell

Benjamin Bouchacourt, Valerio Maisano, Ana Benzaquen, Angela Granata, Sabine Furst, Faezeh Legrand, Thomas Pagliardini, Sandrine Loron, Samia Harbi, Pierre-Jean Weiller, Marie-Joelle Mozziconacci, Claude Lemarie, Boris Calmels, Christian Chabannon, Didier Blaise, Raynier Devillier

Blood (2021) 138 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2021-151187

Published: 2021

Journal Articles

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Raynier Devillier, Sabine Furst, Agnes boyer Chammard, Thomas Pagliardini, Samia Harbi, Valerio Maisano, Angela Granata, Faezeh Legrand, Jihane Pakradouni, jean Marie Boher, Cyril Fauriat, Anne-Sophie Chretien, Christian Chabannon, Norbert Vey, Eric Vivier, Daniel Olive, Didier Blaise

Blood (2021) 138 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2021-150730

Published: 2021

Journal Articles

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier, Boris Calmels, Pharm.D., Sophie Guia, Cyril Fauriat, Sabine Furst, Samia Harbi, Angela Granata, MD, Sophie Ugolini, Christian Chabannon, MD PhD, Daniel Olive, MD PhD, Eric Vivier, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140753

Published: 2020

Journal Articles

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Sabine Furst, Valerio Maisano, MD, Agnes Basire, Angela Granata, MD, Faezeh Legrand, MD, Raynier Devillier, Samia Harbi, Luca Castagna, MD, Christophe Picard, Claude Lemarie, Pharm.D., Christian Chabannon, MD PhD, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142473

Published: 2020

Journal Articles

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Blood (2019) 134 (Supplement_1): 4614.

https://doi.org/10.1182/blood-2019-128004

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients

Blood (2019) 134 (Supplement_1): 4625.

https://doi.org/10.1182/blood-2019-131845

Published: 2019

Journal Articles

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Jacopo Mariotti, Stefania Bramanti, Raynier Devillier, MD PhD, Barbara Sarina, Sabine Furst, MD, Angela Granata, MD, Valerio Maisano, MD, Thomas Pagliardini, MD, Chiara De Philippis, MD, Catherine Faucher, MD, Samia Harbi, MD, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Reda Bouabdallah, Armando Santoro, Didier Blaise, MD PhD, Luca Castagna

Blood (2019) 134 (Supplement_1): 4484.

https://doi.org/10.1182/blood-2019-125101

Published: 2019

NARROW

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Feasibility of Cellular Therapies in HIV Infected Patients: A Monocentric Retrospective Analysis

Prep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation

Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic - a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Higher Grade Cytokine Release Syndrome Is a Predictive Factor for Gvhd in Haploidentical Stem Cell Transplantation with Peripheral Blood Cell

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only